Payer
The new firm will offer partners an expanded range of methods and workflows for small-molecule and peptide drug discovery.
Hippocratic AI will integrate its generative AI agents to support triage and patient intake.
Patients will have 24/7 access to personalized speech, language and cognitive therapies.
The company will use the funds to augment key content partnerships.
The company will use the funds to move into the female health space and increase screening and preventive care.
The funds will be used to increase the development of GAIA-based Alzheimer's disease drugs and widen the pipeline of blockbuster drug candidates.
AI and synthetic-driven research can help clinicians gain a patient's trust, according to Adrienne Boissy, Qualtrics CMO.
The funds will be used to improve the company's flight cadence and expand its pharmaceutical lab capabilities.
In a panel discussion, experts emphasized that AI must align with clinical workflows, reduce cognitive load, and support – not replace – clinicians.
The company will use the funds to increase the adoption of its new offering, Sage, across healthcare providers, payers and care management organizations.